Forecast
The analysts' average price target is €3.41 (+127.33%). The median is €3.41 (+127.33%).
| Buy |
2 |
| Hold |
4 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Lava Therapeutics delisted from Nasdaq following acquisition by XOMA
The shares of Lava Therapeutics were delisted from the Nasdaq Global Select Market after the completion of the acquisition by XOMA Royalty Corporation. XOMA acquired approximately 91.1% of the outstanding common shares at the offer price of $1.04 plus CVR, after the offer and tender period had expired. Lava Therapeutics plans a voluntary delisting, the termination of SEC reporting obligations via Form 15, and records the departures of Stephen Hurly and Fred Powell from management. » More on de.investing.com
Lava Therapeutics: shareholders approve new directors and downstream merger
At an extraordinary general meeting in Amsterdam, shareholders approved the conditional appointment of Owen Hughes as executive director and the appointments of Thomas Burns, Bradley Sitko and Maricel Montano as non‑executive directors. Shareholders discharged the board for its actions up to the date of the meeting. Two resolutions were also passed concerning the planned downstream merger with LAVA Therapeutics New Topco B.V. and the cancellation of the outstanding A shares of New Topco upon the transaction becoming effective. As of the record date, 26,305,295 ordinary shares were outstanding; 63.45% of the shares were represented. » More on de.investing.com
Financials
In the last quarter, LAVA Therapeutics Aktie had revenue of €0 and net profit of -€6.13m
| (EUR) | September 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -2.56k | - |
| Net profit | -6.13m | - |
| EBITDA | -6.12m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €41.66m |
Number of shares | 26.31m |
52-week high/low | €1.82 - €0.77 |
| Dividends | No |
Beta | 0.50 |
P/E ratio | -2.95 |
PEG ratio | -0.22 |
P/B ratio | 3.69 |
P/S ratio | 0.00 |
Company profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
| Name | LAVA Therapeutics Aktie |
| CEO | Stephen Allen Hurly |
| Headquarters | Utrecht,
Netherlands |
| Website | |
| Industry | Chemicals |
| IPO | 26/03/2021 |
| Employees | 34 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | LVTX |
Frankfurt | 4PKB.F |
Düsseldorf | 4PKB.DU |
München | 4PKB.MU |